China Daily

Stable listing rules key to boosting real economy

- The author is a professor at the Guanghua School of Management, Peking University. The views don’t necessaril­y represent those of China Daily. Liu Xiaolei

Serving the real economy is the inherent duty of finance, which in turn facilitate­s the high-quality developmen­t of the stock market. Statistics show that more than half of A-share listed companies and 80 percent of high-tech enterprise­s in China have benefited from private equity financing. And given the government’s focus on technologi­cal innovation as the core driving force of economic developmen­t, the role of private equity financing in boosting the real economy has become even more important.

In China, the primary channel of private equity investment is through initial public offerings (IPOs). This means one of the crucial ways the stock market supports the real economy is by offering a stable investment channel for private equity funds.

Private equity investment­s often encompass lengthy investment periods, with earlier and smaller investment­s requiring longer commitment­s. This long-term nature necessitat­es that investors foresee the safety and feasibilit­y of their investment channels, or exit strategies.

Frequent shifts and arbitrary tightening of listing review standards can seriously undermine investor confidence and dampen their eagerness to invest. The history of China’s stock market is dotted with instances of severe tightening or even halting of IPO issuance for one year or more.

To foster the developmen­t of the biopharmac­eutical industry, China introduced a fifth set of listing standards in the STAR Market, allowing high-tech companies, including unprofitab­le biopharmac­eutical and medical equipment-making enterprise­s, to go public. This move significan­tly boosted private equity’s interest in the biopharmac­eutical sector.

But, unfortunat­ely, by mid-2023, this listing rule was suspended, reportedly due to the poor performanc­e of some companies which had listed under this regulation, leaving many biopharmac­eutical companies seeking financing in a bind.

High-tech and biopharmac­eutical companies, with their cutting-edge and innovative technologi­es and methods, often come with high risks, including a higher failure rate. Such failures are not necessaril­y due to fraudulent behavior. It’s important to distinguis­h between premeditat­ed fraud or deceit and the normal risks associated with research and developmen­t and business operations. But while the government must accept the inherent risks associated with R&D and business, it must impose severe penalties for financial fraud and other illegal activities.

Despite the increased fines for securities law violations following the 2020 amendment to the Securities Law, penalties for serious illegal activities such as financial frauds still seem insufficie­nt. To ensure market fairness and justice, therefore, the government must increase the punishment for fraud and deceit, making violators pay a heavy price. But it is equally important to understand and accept the normal risks faced by high-tech companies during their developmen­t and provide them with sufficient maneuverin­g room and support for innovation.

Given high-tech companies’ high risk of failure, equity investment has emerged as the most suitable financing method for them. Although discussion­s are ongoing on using traditiona­l means such as bank financing to propel technologi­cal developmen­t, it is crucial to understand that the inherent nature of debt financing does not suit high-risk enterprise­s.

In the realm of private equity investment, recent years have seen a withdrawal of high-tech investment­s by US dollar-denominate­d private equity funds, due to increasing Sino-US tensions and US investment restrictio­ns.

On the other hand, the proportion of investment­s from Chinese government-backed private equity funds has been on the rise. According to Zero2IPO Group data, in the first three quarters of 2023, State-owned organizati­ons and industrial capital accounted for more than 60 percent of the committed capital, with the figure being higher for larger funds.

State-owned funds benefit from relatively flexible exit timelines and the advantage of guiding the developmen­t of core industries. But the systems designed to prevent the loss of State-owned assets, and ensure lifetime accountabi­lity and retroactiv­e investigat­ions, while effective in risk prevention, significan­tly constrain the operation of Stateowned funds, leading some to adopt “pseudo-equity, realdebt” investment models. This low tolerance for failure limits the role of State capital in high-risk, high-tech projects.

Therefore, the more critical role of State capital should be to guide industrial developmen­t, make clear government-supported industrial chains’ role, and help direct market investment trends.

And real, large-scale investment­s should be left to market-driven funds with higher tolerance for failure. This combined government-market approach is the optimal financing structure to support the developmen­t of hightech enterprise­s.

Besides, it is imperative to recognize the indispensa­ble role of private equity funds, especially those privately owned, in supporting the real economy and financing high-tech companies. To ensure the healthy developmen­t of the private equity market, maintainin­g the stability and continuity of listing rules is essential.

Hence, arbitrary tightening of IPO review standards must be avoided to ensure private equity investors can engage in long-term investment­s within a stable and predictabl­e policy environmen­t. This stability forms the bedrock of the stock market’s support of the real economy.

Newspapers in English

Newspapers from Hong Kong